Recent success in treating BRCA1/2 deficient cancers, and our data showing that resistant cells with MMR mutations are sensitive to TMZ and ABT-888, leads us to speculate that treatment of sensitive tumours with a PARP inhibitor might thwart the emergence of MMR-mediated TMZ resistance. This evidence concerns the gene PARP1 and cancer.